GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyundai Bioscience Co Ltd (XKRX:048410) » Definitions » Cyclically Adjusted Revenue per Share

Hyundai Bioscience Co (XKRX:048410) Cyclically Adjusted Revenue per Share : ₩829.34 (As of Mar. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Hyundai Bioscience Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Hyundai Bioscience Co's adjusted revenue per share for the three months ended in Mar. 2024 was ₩127.807. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₩829.34 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Hyundai Bioscience Co's average Cyclically Adjusted Revenue Growth Rate was -6.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -17.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -25.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Hyundai Bioscience Co was -17.10% per year. The lowest was -36.50% per year. And the median was -31.10% per year.

As of today (2024-06-08), Hyundai Bioscience Co's current stock price is ₩19570.00. Hyundai Bioscience Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₩829.34. Hyundai Bioscience Co's Cyclically Adjusted PS Ratio of today is 23.60.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hyundai Bioscience Co was 44.24. The lowest was 0.41. And the median was 5.80.


Hyundai Bioscience Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Hyundai Bioscience Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyundai Bioscience Co Cyclically Adjusted Revenue per Share Chart

Hyundai Bioscience Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,398.32 1,486.79 1,055.17 910.84 846.85

Hyundai Bioscience Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 884.31 868.74 873.71 846.85 829.34

Competitive Comparison of Hyundai Bioscience Co's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Hyundai Bioscience Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyundai Bioscience Co's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyundai Bioscience Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Hyundai Bioscience Co's Cyclically Adjusted PS Ratio falls into.



Hyundai Bioscience Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hyundai Bioscience Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=127.807/118.8477*118.8477
=127.807

Current CPI (Mar. 2024) = 118.8477.

Hyundai Bioscience Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 189.107 99.353 226.213
201409 217.400 99.608 259.392
201412 307.815 99.098 369.161
201503 355.570 99.720 423.773
201506 449.163 100.050 533.553
201509 247.216 100.110 293.488
201512 255.674 100.220 303.196
201603 332.772 100.560 393.289
201606 236.925 100.790 279.373
201609 276.417 101.460 323.788
201612 359.649 101.560 420.869
201703 197.822 102.850 228.592
201706 193.743 102.610 224.402
201709 243.109 103.490 279.186
201712 366.718 102.990 423.183
201803 198.745 104.100 226.901
201806 309.123 104.130 352.814
201809 249.726 105.650 280.922
201812 210.826 104.350 240.117
201903 224.735 104.490 255.615
201906 232.862 104.880 263.874
201909 194.065 105.200 219.241
201912 218.336 105.120 246.849
202003 117.006 105.540 131.759
202006 93.825 104.870 106.331
202009 82.759 106.200 92.615
202012 54.477 105.765 61.215
202103 54.282 107.357 60.092
202106 63.593 107.579 70.255
202109 50.364 108.759 55.036
202112 65.202 109.676 70.654
202203 60.368 111.806 64.170
202206 35.781 114.083 37.275
202209 60.361 114.831 62.472
202212 43.074 115.200 44.438
202303 79.932 116.550 81.508
202306 80.970 117.140 82.150
202309 49.320 119.111 49.211
202312 28.628 118.848 28.628
202403 127.807 118.848 127.807

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Hyundai Bioscience Co  (XKRX:048410) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Hyundai Bioscience Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=19570.00/829.34
=23.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hyundai Bioscience Co was 44.24. The lowest was 0.41. And the median was 5.80.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Hyundai Bioscience Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Hyundai Bioscience Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyundai Bioscience Co (XKRX:048410) Business Description

Industry
Traded in Other Exchanges
N/A
Address
150 North-Ahyun Road, 3rd Floor Academic Cooperation Building, Ehwa Women’s University, Seodaemun-gu, Seoul, KOR
Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.

Hyundai Bioscience Co (XKRX:048410) Headlines

No Headlines